NYSE$ATR

AptarGroup Inc. · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Reported a strong quarter with sales and net income increasing, driven by core sales growth and pricing initiatives.

AptarGroup reported a positive second quarter with a 4% increase in reported sales and a 15% increase in net income. Core sales grew by 10%, and adjusted EBITDA increased by 8%. The company is focused on pricing initiatives and managing expenses to drive shareholder return.

  • Reported sales grew 4% and net income increased 15% to $64 million.
  • Core sales increased 10% and adjusted EBITDA increased 8% to $160 million.
  • Reported earnings per share increased 17% to $0.95 compared to $0.81 in the prior year.
  • Each segment achieved sales growth through improved volume as well as increased pricing, with Pharma and Beauty + Home segments reaching double-digit core sales growth.

Headline financials

Total Revenue

$845M

Previous: $811M+4.1%
EPS (adj)

$0.96

Previous: $0.91+5.5%
Total Core Sales Growth

10.0%

Previous: 10.0%+0.0%
Pharma Core Sales Growth

12.0%

Previous: 2.0%+500.0%
Beauty Core Sales Growth

10.0%

Previous: 13.0%-23.1%
Closures Core Sales Growth

8.0%

Previous: 23.0%-65.2%
Capital Expenditures

-$147M

Previous: -$137M-7.5%
Free Cash Flow

-$83.6M

Previous: -$81.8M-2.3%
Net Income

$63.6M

Previous: $55.3M+15.1%
Operating Income

$101M

Previous: $84.4M+19.9%
Gross Profit

$845M

Previous: $811M+4.1%
Cash & Equivalents

$240M

Previous: $291M-17.5%
Total Assets

$4.26B

Previous: $4.11B+3.6%
Stock-Based Comp

$8.77M

Previous: $10.3M-14.9%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$845M

Q2 2022+4.1%vs Q2 2021
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

AptarGroup · $845M total across 3 segments · Q2 2022

  • Beauty
    $371M+3.1%
  • Pharma
    $340M+4.6%
  • Closures
    $133M+6.0%

Forward guidance

Aptar expects earnings per share for the third quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.90 to $1.00.

Tailwinds

  • Pharma segment’s prescription drug and consumer health care markets are expected to continue strong momentum in the coming quarter.
  • Well positioned to navigate a potential economic downturn due to the strength of our balance sheet
  • Disciplined approach to capital management
  • Broad portfolio of innovative solutions
  • Serve multiple essential markets

Headwinds

  • Rising inflation
  • Ongoing war in Ukraine
  • Supply chain disruptions
  • Very tight U.S. labor market
  • The stronger dollar is expected to continue to have an impact on our results.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro